UOC
LGND icon

UBS O'Connor’s Ligand Pharmaceuticals LGND Stock Holding History

UBS O'Connor’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,773
Closed -$519K – 464
2016
Q1 		$519K Buy
+7,773
New +$472K 0.01% 359

Other funds holding LGND

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

UBS O'Connor's LGND Position: Q2 2016 in Review

UBS O'Connor sold out of Ligand Pharmaceuticals (LGND) in Q2 2016, closing a stake of 7,773 shares — an estimated $519K sold.

UBS O'Connor first reported a position in LGND in Q1 2016 and held it in 1 quarter. The position peaked at $519K in Q1 2016. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2016.

  • UBS O'Connor reported no remaining Ligand Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 7,773 Ligand Pharmaceuticals shares in Q2 2016, an estimated $519K.
  • UBS O'Connor first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • UBS O'Connor's Ligand Pharmaceuticals position peaked at $519K in Q1 2016.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.